Pyoderma Gangrenosum with Biological Agents Therapy: A Systematic Review
Difference in effective rate shows no statistical significance between two kinds of agents. However, IL inhibitors demonstrate an advantage with shorter treatment cycles. Additionally, Infliximab has a wider range of side effects and should be used with caution.PROSPERO number: CRD42024608039.
Authors
- Jia He (ORCID: https://orcid.org/0000-0002-7717-8574)
- Xincai Xiong
- Xi Duan (ORCID: https://orcid.org/0000-0003-0192-9607)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-0580-0889)
- Bin Tan (ORCID: https://orcid.org/0000-0001-8219-9970)
- Meng Chen (ORCID: https://orcid.org/0009-0005-3537-9027)
- Xinru Hu (ORCID: https://orcid.org/0009-0000-4740-2646)
- Yunzhu Mou
- Shuang Du (ORCID: https://orcid.org/0009-0000-3976-708X)
Institutions
- Affiliated Hospital of North Sichuan Medical College (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/ccid.s571049
- Primary Topic
- Autoimmune and Inflammatory Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00